Connect Biopharma (NASDAQ:CNTB – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports.
Connect Biopharma Stock Performance
CNTB stock traded down $0.03 during trading on Monday, hitting $0.64. 485,502 shares of the company’s stock traded hands, compared to its average volume of 1,360,443. The stock has a market capitalization of $40.49 million, a price-to-earnings ratio of -0.54 and a beta of 0.06. Connect Biopharma has a 52 week low of $0.60 and a 52 week high of $3.82. The stock has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $2.11. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on CNTB. BTIG Research decreased their target price on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Oppenheimer cut their price objective on shares of Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, September 22nd. Leerink Partners started coverage on Connect Biopharma in a research note on Monday, October 12th. They set an “outperform” rating and a $4.00 target price for the company. Weiss Ratings lowered Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Connect Biopharma in a report on Wednesday, October 28th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Connect Biopharma has a consensus rating of “Moderate Buy” and an average target price of $5.88.
Check Out Our Latest Stock Analysis on Connect Biopharma
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
See Also
- Five stocks we like better than Connect Biopharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
